This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / UniQure Faces Class Action Over...
Regulatory class action lawsuit

UniQure Faces Class Action Over AMT-130 FDA Approval

Analysis based on 9 articles · First reported Feb 10, 2026 · Last updated Feb 17, 2026

Sentiment
-60
Attention
4
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of UniQure's alleged misleading statements, leading to a significant drop in UniQure's stock price. This event highlights regulatory risks in the biotechnology sector and could lead to increased scrutiny of other companies' drug development disclosures.

Biotechnology Pharmaceuticals Legal Services
Event Summary

A class action lawsuit has been filed against UniQure N.V. by Robbins LLP on behalf of investors who purchased ordinary shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that UniQure misled investors regarding the likelihood of FDA approval for its leading drug candidate, AMT-130. Specifically, it claims that the design of UniQure's Pivotal Study was not fully approved by the United States===Food and Drug Administration, and the company downplayed the need for additional studies. On November 3, 2025, UniQure announced that the United States===Food and Drug Administration no longer agreed that the data from its Phase I/II studies for AMT-130 would be adequate for a BLA submission, causing UniQure's stock to plummet over 49%.

Key Actions
100 Robbins LLP filed class action lawsuit UniQure
95 UniQure misled investors regarding FDA approval likelihood
90 United States===Food and Drug Administration provided negative feedback on AMT-130's BLA path UniQure
90 UniQure stock price plummeted
85 UniQure announced FDA feedback on AMT-130
Entities Involved
stock
UniQure
UniQure is facing a class action lawsuit for allegedly misleading investors about the FDA approval likelihood of its drug candidate, AMT-130. This news caused its ordinary shares to plummet by over 49%. The company's reputation and stock price are severely negatively impacted.
Importance 100 Sentiment -90
priv
Robbins LLP
Robbins LLP filed a class action lawsuit against UniQure on behalf of investors. The firm is actively investigating the allegations and representing shareholders, which could enhance its reputation in shareholder rights litigation.
Importance 80 Sentiment 70
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration's feedback to UniQure regarding the AMT-130's path to BLA approval is central to the lawsuit. The FDA's disagreement with UniQure's data design directly led to the stock price drop and the lawsuit.
Importance 70 Sentiment 0
exch
Nasdaq
Nasdaq is the exchange where UniQure's ordinary shares are traded. The stock's significant drop occurred on this exchange.
Importance 10 Sentiment 0
Relationships
Robbins LLP related ↔ UniQure
United States===Food and Drug Administration related ↔ UniQure
Robbins LLP related ↔ United States===Food and Drug Administration
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.